Kathryn V Holmes

US Patent:

20030211477, Nov 13, 2003

Filed:

May 1, 2002

Appl. No.:

10/138176

Inventors:

Kathryn Holmes - Golden CO, US
Bruce Zelus - Lakewood CO, US
Kemin Tan - Waltham MA, US
Jia-Huai Wang - Belmont MA, US
Rob Meijers - Sommerville MA, US

International Classification:

C12Q001/70
C12Q001/68
C07K002/00
C07K004/00
C07K005/00
C07K007/00
C07K014/00
C07K016/00
C07K017/00
A61K038/00
C07K001/00

US Classification:

435/006000, 435/005000, 530/300000, 530/350000

Abstract:

Disclosed is the first crystal structure in the carcinoembryonic antigen (CEA) family, the mouse CEACAM1a[1,4], containing the N-terminal functional domain that is characterized as having a uniquely folded CC′ loop. This novel feature could not be predicted based on sequence analysis alone. The structure has provided a prototypic architecture for modeling human homologues within the CEA family. These tertiary structures are used in a number of screening methods for identifying candidate molecules that have a binding affinity for the tertiary structure of the CC′ loop and its vicinity. Pharmaceutical preparations that include one or more of such identified candidates may then be provided and used in treatments for certain bacterial and viral infections, certain tumors and disorders of angiogenesis or immune responses and autoimmune disease.

US Patent:

20040237128, Nov 25, 2004

Filed:

Jun 24, 2004

Appl. No.:

10/473424

Inventors:

Nicole Beauchemin - Montreal, CA
Claire Turbide - Montreal, CA
Kathryn Holmes - Golden CO, US
Dianna Blau - Jacksonville FL, US
Stephanie Letourneau - Montreal, CA

International Classification:

A01K067/027

US Classification:

800/018000

Abstract:

The present invention relates to a transgenic animal having a disruption of at least one allele of the Ceacam1 gene and method of making same. More particularly, the present invention relates to transgenic mouse whose germ cells and somatic cells contain a knockout mutation in DNA encoding CEACAM1or CEACAM1. In a particular embodiment, mice containing a disruption of at least one of the Ceacam1 gene present a reduced expression of the CEACAM1protein. The present invention also relates to a transgenic mouse comprising a disruption of the Ceacam1 gene wherein the mouse expresses at least a reduced level of CEACAM1relative to a corresponding wild-type mouse and methods of making same.

US Patent:

20120009212, Jan 12, 2012

Filed:

Jan 26, 2011

Appl. No.:

13/014664

Inventors:

Robert S. HODGES - Denver CO, US
Kathryn V. Holmes - Golden CO, US
Zhe Yan - Lakewood CO, US
Wendy J. Hartsock - Aurora CO, US
Zhaohui Qian - Colorado Springs CO, US
Brooke Elizabeth Bishop Hirsch - Broomfield CO, US

International Classification:

A61K 39/385
A61P 31/12
A61P 37/04
C07K 17/02
C07K 17/10

US Classification:

42419611, 530405, 530363, 530367, 530395

Abstract:

Templated conjugates created from naturally-occurring protein sequences found in pathogens, such as viruses, are disclosed. The sequences are “templated” into a consensus coiled-coil sequence in order to form a two-stranded antigen suitable for immunization of a subject.

US Patent:

20120014972, Jan 19, 2012

Filed:

Jan 26, 2011

Appl. No.:

13/014682

Inventors:

Robert S. Hodges - Denver CO, US
Brooke Elizabeth Bishop Hirsch - Broomfield CO, US
Zhe Yan - Lakewood CO, US
Kathryn V. Holmes - Golden CO, US
Zhaohui Qian - Colorado Springs CO, US
Wendy Hartsock - Aurora CO, US

International Classification:

A61K 39/145
C07K 16/10
A61P 31/16
A61K 39/42
C07K 19/00
C07K 17/02
C07K 16/46

US Classification:

4241591, 530324, 4242101, 5303894, 5303873, 5303883, 42419611, 530323

Abstract:

The disclosure relates at least in part to embodiments of compositions and methods including vaccines for protection against multiple serologically distinct strains of influenza virus. This disclosure provides significant advances and addresses important needs in the influenza vaccine field.

US Patent:

20030190600, Oct 9, 2003

Filed:

Apr 5, 2002

Appl. No.:

10/118471

Inventors:

Kathryn Holmes - Golden CO, US
Bruce Zelus - Lakewood CO, US
Kemin Tan - Waltham MA, US
Jia-Huai Wang - Belmont MA, US
Rob Meijers - Somerville MA, US

International Classification:

A01N037/18
A61K038/00
C12Q001/70
G01N033/53
C07K001/00
C07K014/00
C07K017/00

US Classification:

435/005000, 435/007100, 530/350000, 514/002000

Abstract:

Disclosed are novel crystal structures of a carcinoembryonic cell adhesion antigen functional domain that is characterized as having a unique N-terminal domain structure, called a CC′ loop. This tertiary structure is used in a number of screening methods for identifying candidate molecules that have a binding affinity for the tertiary structure of the CC′ loop. Pharmaceutical preparations that include one or more of such identified candidate may then be provided and used in treatments for bacterial infections, dysentery, angiogenesis, immune cell mediated disease, and related conditions thereto.

US Patent:

20140154282, Jun 5, 2014

Filed:

Jan 26, 2012

Appl. No.:

13/981300

Inventors:

Robert S. Hodges - Denver CO, US
Kathryn V. Holmes - Golden CO, US
Zhe Yan - Lakewood CO, US
Wendy Jeanne Hartsock - Aurora CO, US
Zhaohui Qian - Colorado Srings CO, US
Brooke Elizabeth Bishop Hirsch - Broomfield CO, US

International Classification:

A61K 39/145

US Classification:

4241861, 530324, 530350, 530363, 530367, 530322

Abstract:

Templated conjugates created from naturally-occurring protein sequences found in pathogens, such as viruses, are disclosed. The sequences are “templated” into a consensus coiled-coil sequence in a platform in order to form a two-stranded antigen suitable for immunization of a subject.